Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
Aziz Nazha, Stefan Faderl(Jazz Pharmaceuticals (United States)), Jörge E. Cortes(Augusta University Health), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Mark Brandt(The University of Texas MD Anderson Cancer Center), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Zeev Estrov(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Steve Kornblau(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Min Du(Southern University of Science and Technology), Sangbum Choi(The University of Texas MD Anderson Cancer Center)
Cited by 53
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k